trending Market Intelligence /marketintelligence/en/news-insights/trending/af0M9VBy33p2_RxVqZ-tEA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

CFDA approves clinical trials for Sihuan's erectile dysfunction drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


CFDA approves clinical trials for Sihuan's erectile dysfunction drug

The China Food and Drug Administration granted approval to Sihuan Pharmaceutical Holdings Group Ltd. for phase 1, 2 and 3 clinical trials of Fadanafil, a drug for benign prostatic hyperplasia-induced lower urinary tract symptoms and erectile dysfunction.

The drug is being developed by Shandong XuanZhu Pharma Co. Ltd., a unit of Sihuan Pharmaceutical.